You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 10,786,552


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,786,552
Title:Il-2R.beta.-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody
Abstract: The invention relates to (among other things) a method of administering to a patient suffering from a cancer, the method comprising the steps of: (a) administering an IL-2R.beta.-activating amount of a long acting, IL-2R.beta.-selective agonist; and (b) administering a CTLA-4 pathway-inhibiting amount of an anti-CTLA-4 antibody or a PD-1 pathway-inhibiting amount of an anti-PD-1 antibody.
Inventor(s): Addepalli; Murali Krishna (Secunderabad, IN), Charych; Deborah H. (Albany, CA), Kantak; Seema (Pacifica, CA), Lee; Steven Robert (San Lorenzo, CA)
Assignee: Nektar Therapeutics (San Francisco, CA)
Application Number:15/997,487
Patent Claims:1. A method of treating a patient suffering from a solid cancer, the method comprising the steps of: (a) administering to the patient an IL-2R.beta.-activating amount of a long acting, interleukin-2 receptor beta (IL-2R.beta.)-selective agonist of a formula: ##STR00003## or a pharmaceutically acceptable salt form thereof, wherein IL-2 is an interleukin-2, and (n) ranges from 3 to 4,000; and (b) administering to the patient a PD-1 pathway-inhibiting amount of an anti-PD-1 antibody, wherein step (a) is carried out before, after or simultaneously with step (b).

2. The method of claim 1, wherein the patient is a human.

3. The method of claim 1, wherein the cancer is melanoma.

4. The method of claim 2, wherein the solid cancer is selected from the group consisting of breast cancer, ovarian cancer, colon cancer, colorectal cancer, gastric cancer, malignant melanoma, liver cancer, small cell lung cancer, non-small cell lung cancer, thyroid cancers, kidney cancer, cancer of the bile duct, brain cancer, cervical cancer, maxillary sinus cancer, bladder cancer, esophageal cancer, Hodgkin's disease and adrenocortical cancer.

5. The method of claim 1, wherein the cancer is colon cancer.

6. The method of claim 1, wherein the cancer is breast cancer.

7. The method of claim 1, wherein step (a) is carried out prior to step (b) being carried out.

8. The method of claim 1, wherein step (a) is carried out after step (b) is carried out.

9. The method of claim 1, wherein steps (a) and (b) are carried out simultaneously.

10. The method of claim 1, wherein step (a) comprises parenterally administering to the patient the long acting, interleukin-2 receptor beta (IL-2R.beta.)-selective agonist.

11. The method of claim 1, wherein step (b) comprises parenterally administering to the patient the anti-PD-1 antibody.

12. The method of claim 10, wherein step (a) comprises intravenous administration of the long acting, interleukin-2 receptor beta (IL-2R.beta.)-selective agonist.

13. The method of claim 11, wherein step (b) comprises intravenous administration of the anti-PD-1 antibody.

14. The method of claim 1, wherein the long-acting, interleukin-2 receptor beta (IL-2R.beta.)-selective agonist comprises no more than ten mole percent of compounds having a formula, ##STR00004## or pharmaceutically acceptable salts thereof, where IL-2 is an interleukin-2, and (n) ranges from 3 to 4,000.

15. The method of claim 14, wherein the long acting, interleukin-2 receptor beta (IL-2R.beta.)-selective agonist comprises no more than five mole percent of compounds having a formula, ##STR00005## or pharmaceutically acceptable salts thereof, where IL-2 is an interleukin-2, and (n) ranges from 3 to 4,000.

16. The method of claim 1, where the anti-PD-1 antibody is selected from nivolumab, lambrolizumab (pembrolizumab), MDPL3280A (atezolizumab), MEDI4736 (durvalumab) and MSB0010718C (avelumab).

17. The method of claim 1, wherein each ##STR00006## moiety comprised in the long acting, interleukin-2 receptor beta (IL-2R.beta.)-selective agonist has a molecular weight of about 20 kilodaltons.

18. The method of claim 1, wherein the interleukin-2 is aldesleukin.

Details for Patent 10,786,552

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Clinigen, Inc. PROLEUKIN aldesleukin For Injection 103293 05/05/1992 ⤷  Try a Trial 2034-02-21
Merck Sharp & Dohme Corp. KEYTRUDA pembrolizumab For Injection 125514 09/04/2014 ⤷  Try a Trial 2034-02-21
Merck Sharp & Dohme Corp. KEYTRUDA pembrolizumab Injection 125514 01/15/2015 ⤷  Try a Trial 2034-02-21
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.